Abstract Library

#4638 Prognostic role of the kynurenine/tryptophan pathway and inflammatory cytokines in neuroendocrine tumour progression: A cross-sectional analysis

Introduction: Indoleamine-2,3-dioxygenase (IDO) converts L-tryptophan (T) to L-kynurenine (K) resulting in an immunosuppressive microenvironment.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Pecora G, Salerno G, Lionetto L, Visco V,

Keywords: Neuroendocrine Tumour, tryptophan, kynurenine, cytokines, immunotherapy, Indoleamine-2-3-dioxygenase,

#4248 Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients

Introduction: The majority of NET patients experience recurrent disease after curative surgery. There is a need for prognostic biomarkers in this patient group.

Conference:

Presenting Author: Johansen S

Authors: Johansen S, Hansen T, Goll R, Florholmen J,

Keywords: Plasma Tryptophan Metabolites, Prognostic Biomarker, Recurrent Disease after Curative Surgery,

#4228 Evaluation of the impact of indoleamine 2,3-deoxygenase (IDO) enzyme activity in neuroendocrine tumors (NETs)

Introduction: Indoleamine 2,3-deoxygenase (IDO) enzyme, by inducing L-tryptophan (Trp) depletion and L-kynurenine (kyn) accumulation, contributes to the formation of an immunosuppressive microenvironment. Some studies highlighted that patient with cancer in treatment with immune checkpoint inhibitors (ICI) and with low Kyn/Trp values showed a better PFS and OS, but there are no data for NETs.

Conference:

Presenting Author: Mancini C

Authors: Mancini C, Mazzilli R, Zamponi V, Motta C, Salerno G,

Keywords: neuroendocrine tumor, IDO enzyme, Kyn/Trp ratio, immunotherapy,

#4187 Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors

Introduction: Cognitive and psychiatric problems are common in cancer patients, but literature in patients with neuroendocrine tumors (NET) is scarce. Peripheral serotonin overproduction by the tumor, clinically manifesting as carcinoid syndrome, is hypothesized to be related to cognitive and psychiatric problems, through depletion of serotonin’s precursor tryptophan.

Conference:

Presenting Author: Tesselaar M

Authors: Luijendijk M, Tesselaar M, van Rossum H, Korse C, Verbeek W,

Keywords: Neuroendocrine neoplasm, carcinoid syndrome, cognitive functioning, depression, anxiety, serotonin, tryptophan, 5-HIAA,

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,